robot: Update article (please report if you notice any mistake or error in this edit)
imported>DaxServer m (Add back cat per discussion WP:TCAT using Pywikibot category add) |
(robot: Update article (please report if you notice any mistake or error in this edit)) |
||
| Line 17: | Line 17: | ||
| key_people = {{Unbulleted list|Dr. P A Mody, Chairman & [[Managing Director|MD]]<ref>{{cite web|url=http://www.indiainfoline.com/Research/LeaderSpeak/Dr-P-A-Mody-CEO-Unichem-Laboratories-Ltd./11416636 |title=Interview of Dr P A Mody, CEO, Unichem Laboratories Ltd |publisher=Indiainfoline.com |accessdate=3 October 2010}}</ref>|Mr. Dilip Kunkolienkar ([[Director Technical]])<ref>{{cite web|url=http://www.moneycontrol.com/news/announcements/unichem-lab-appoints-mr-bhagwat-s-dhingra-as-chief-executive-domestic-pharma_744360.html |title=Unichem Lab appoints Mr. Dilip Kunkolienkar as Director Technical-Domestic Pharma |date=13 August 2012 |website=[[Moneycontrol.com]]}}</ref>}} | | key_people = {{Unbulleted list|Dr. P A Mody, Chairman & [[Managing Director|MD]]<ref>{{cite web|url=http://www.indiainfoline.com/Research/LeaderSpeak/Dr-P-A-Mody-CEO-Unichem-Laboratories-Ltd./11416636 |title=Interview of Dr P A Mody, CEO, Unichem Laboratories Ltd |publisher=Indiainfoline.com |accessdate=3 October 2010}}</ref>|Mr. Dilip Kunkolienkar ([[Director Technical]])<ref>{{cite web|url=http://www.moneycontrol.com/news/announcements/unichem-lab-appoints-mr-bhagwat-s-dhingra-as-chief-executive-domestic-pharma_744360.html |title=Unichem Lab appoints Mr. Dilip Kunkolienkar as Director Technical-Domestic Pharma |date=13 August 2012 |website=[[Moneycontrol.com]]}}</ref>}} | ||
| industry = [[Pharmaceutical]] & healthcare | | industry = [[Pharmaceutical]] & healthcare | ||
| num_employees = | | num_employees = Over 3100 | ||
| parent = [[Unichem Laboratories Limited]] | | parent = [[Unichem Laboratories Limited]] | ||
| subsid = Unichem Pharmaceuticals (USA) INC;<ref name="ReferenceA">{{cite web|url=http://www.unichemlabs.com/global-operations.html |title=Pharmaceutical Business, Pharma Business Development - Unichem Laboratories |publisher=Unichemlabs.com |accessdate=3 October 2010}}</ref> Niche Generics Limited;<ref>{{cite web|url=http://www.business-standard.com/india/news/indian-pharma-firms-swallow-bitter-pill-in-us-europe/364075/ |title=Indian pharma firms swallow bitter pill in US, Europe |work=Business Standard |date=16 July 2009 |accessdate=3 October 2010}}</ref> Unichem Laboratories Limited, Ireland; Unichem FarmaceuticaDo Brasil Ltda, Brazil; Unichem SA (Pty) Limited, South Africa<ref name="ReferenceA" /> | | subsid = Unichem Pharmaceuticals (USA) INC;<ref name="ReferenceA">{{cite web|url=http://www.unichemlabs.com/global-operations.html |title=Pharmaceutical Business, Pharma Business Development - Unichem Laboratories |publisher=Unichemlabs.com |accessdate=3 October 2010}}</ref> Niche Generics Limited;<ref>{{cite web|url=http://www.business-standard.com/india/news/indian-pharma-firms-swallow-bitter-pill-in-us-europe/364075/ |title=Indian pharma firms swallow bitter pill in US, Europe |work=Business Standard |date=16 July 2009 |accessdate=3 October 2010}}</ref> Unichem Laboratories Limited, Ireland; Unichem FarmaceuticaDo Brasil Ltda, Brazil; Unichem SA (Pty) Limited, South Africa<ref name="ReferenceA" /> | ||
| Line 39: | Line 39: | ||
The Company has a functional Biotech R&D Centre and a Pilot Plant at Goa. Bio-similar R&D is based on recombinant DNA platform. Microbial fermentation and protein purification are its strengths. The cell culture facility in the Biotech R&D is capable of handling mammalian cell lines for screening novel biological and chemical entities.{{cn|date=March 2021}} | The Company has a functional Biotech R&D Centre and a Pilot Plant at Goa. Bio-similar R&D is based on recombinant DNA platform. Microbial fermentation and protein purification are its strengths. The cell culture facility in the Biotech R&D is capable of handling mammalian cell lines for screening novel biological and chemical entities.{{cn|date=March 2021}} | ||
The Company has made more than 500 product registrations across the world. It has more than | The Company has made more than 500 product registrations across the world. It has more than 70 US ANDA filings, 45 approved ANDAs and more than 60 European submissions. The Company holds 75 US DMF, 26 Certificate of suitability to European Pharmacopeia (CEP) issued by the European Directorate for the Quality of Medicines and Healthcare (EDQM) and several DMFs across the world.{{cn|date=March 2021}} | ||
== References == | == References == | ||